AstraZeneca (AZN) Tops Q2 EPS by 4c

AstraZeneca (NYSE: AZN) reported Q2 EPS of $1.20, $0.04 better than the analyst estimate of $1.16. Revenue for the quarter came in at $6.23 billion versus the consensus estimate of $6.24 billion.

The Board has recommended a first interim dividend of $0.90.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Amphenol (APH) Tops Q1 EPS by 7c, offers guidance
• Amphenol (APH) Reports Q1, Announces $2B Share Buyback
• Simmons First National Corp (SFNC) Misses Q1 EPS by 1c